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Abstract 
Colon adenocarcinoma (CAC) is the second most frequent cancer in Portugal, representing 
10% of all tumors. Although CAC is usually diagnosed in a symptomatic phase, with a level 
of progression around 10 years, the prognosis remains relatively reserved. However, if 
diagnosed at an early stage, 5-year survival rates can reach 50% in both genders. In average, 
in Portugal around 9 to 10 patients die with colon and rectum adenocarcinomas per day. In 
this regard, population-wide screening and early detection of CAC through biomarkers are 
important strategies that can change this situation in the future in order to diminish mortality. 
Matrix Gla Protein (MGP) is an extracellular protein that was previously shown to be 
involved in the inhibition of calcification of arteries and cartilage, although its functional role 
in neoplasia remains unclear, it was shown to be up-regulated in a variety of tumors, 
including ovarian, breast, and gliomas, among others. This fact has triggered our interest in 
analyzing the expression of MGP, as well as some putative regulatory transcription factors, in 
CAC. 
To proceed with this analysis, samples from 20 patients with CAC were analyzed through 
qRT-PCR. Our results show an overexpression of MGP in colon cancer biopsy specimens 
(and cell lines) at mRNA level as compared to normal colon tissue (p = 0.056), contradicting 
a previously published analysis where a down-regulation of this gene was shown for this type 
of cancer. Given these results, we proceeded with our study by analyzing the expression of 
transcription factors that have been described in the literature as having a role in the 
regulation of MGP, and in some cases also in tumorigenesis. From the results obtained, it was 
found that there was an up-regulation of RUNX2 (p = 0.037) and CCBE1 (p = 0.012) mRNA 
levels in CAC samples. Although the expression levels for FGF2 (p = 0.085) and RARα (p = 
0.58) do not present a significant P value, it was found that there was a positive Pearson 
correlation (r = 0.89, p≤0.0001 for FGF2 and r = 0.85, p ≤0.0001 for RARα), demonstrating a 
strong trend towards simultaneous up-regulation of these transcription factors and MGP. In 
the future it is necessary a deeper analysis on how these genes interact with each other and 
what mechanisms are affected with this disruption. 
  
Key words: Colon adenocarcinoma, MGP, Transcription factors, RUNX2, CCBE1, RARα, 
FGF2 
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Resumo 
Em Portugal, o adenocarcinoma do cólon apresenta uma taxa de prevalência em relação a 
outros tumores de 10%, e em média, morrem 9 a 10 pacientes por dia. Embora este tipo de 
tumor seja diagnosticado já numa fase mais avançada e sintomática da doença, com uma 
progressão em cerca de 10 anos, o prognóstico permanece reservado. Contudo, se 
diagnosticado num estadio mais precoce, a taxa de sobrevivência para um período de 5 anos 
apresenta valores acima dos 50%, tanto para homens como para mulheres. De acordo com os 
dados publicados pelo Registo Oncológico do Sul (ROR-Sul) 81% e 71% dos casos foram 
diagnosticados por volta dos 60 anos em homens e mulheres, respectivamente. 
Existem duas formas principais para o aparecimento do adenocarcinoma do cólon, 
nomeadamente, a forma relacionada com o aparecimento esporádico com origem em 
mutações em células somáticas (mais de 95% dos casos) e a forma associada à herança de 
mutações em células da linha germinal (forma hereditária). Associadas às mutações 
transmitidas através de células da linha germinal, temos a síndrome da polipose adenomatosa 
familiar (FAP) e o síndrome não polipoide hereditário ou síndrome de Lynch. No caso da 
síndrome adenomatosa familiar, esta é uma doença hereditária autossómica dominante, e é 
caracterizada por 1) aparecimento de milhares de tumores pré-neoplásicos (pólipos) ao longo 
de todo o tubo digestivo e 2) aparecimento numa idade jovem (40 anos). Associada a esta 
doença está também o gene supressor de tumores APC, responsável maioritariamente pela 
proliferação celular e activação de vias de sinalização apoptóticas. Quando existe uma perda 
por heterozigotia (LOH) do restante alelo funcional este síndrome tem maior risco de vir a dar 
origem a um adenocarcinoma. Existem ainda outros tipos de síndromes associados a este tipo 
e doença, nomeadamente, a síndrome de Gardner, a hipertrofia congénita do pigmento da 
retina e a forma mais suave da polipose adenomatosa familiar. Em relação à síndrome de 
Lynch esta difere da FAP pelo tipo de mutações encontradas em genes associados a 
mecanismos de reparação do ADN como é o caso do MLH1 e MSH2 e por não apresentar 
pólipos pré-neoplásicos em grande número. Já a forma do adenocarcinoma do cólon 
esporádico, está relacionado com o aparecimento de mutações pontuais em células somáticas, 
que podem ser causadas por fatores subjacentes ao dia-a-dia do paciente. No entanto é de 
salientar que para ambas as formas de manifestação do adenocarcinoma do cólon, é 
necessário ocorrer um primeiro evento carcinogénico que altere o normal funcionamento da 
célula. 
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No que diz respeito aos métodos de rastreio para este tipo de tumores, os melhores continuam 
ainda a ser a sigmoidoscopia e colonoscopia total. No entanto, o avanço das técnicas em 
biologia molecular tem vindo a permitir a descoberta de novos genes que estejam envolvidos 
na regulação tumoral e que no futuro possam ser considerados possíveis biomarcadores para 
uma deteção mais precoce e possíveis alvos terapêuticos, a fim de diminuir a mortalidade 
ainda associada a este tipo de tumores. 
A MGP (Proteína Gla da matrix) é uma proteína extracelular cuja principal função está 
associada à inibição da calcificação das artérias e cartilagem. No cancro, embora tenha sido 
demonstrada uma sobre-expressão da MGP numa variedade de tumores, como o cancro do 
ovário, da mama, glioblastomas, entre outros, o seu papel permanece pouco claro,. 
Especificamente, no adenocarcinoma do cólon foi anteriormente demonstrada uma 
desregulação da MGP, embora de forma pouco consistente. Como tal o principal objetivo 
deste trabalho incidiu sobre a análise de expressão do gene MGP, bem como a análise de 
alguns possíveis fatores de transcrição associados à sua regulação em amostras do 
adenocarcinoma do cólon. Para tal, amostras de mucosa normal e tumoral de 20 pacientes 
foram analisadas por PCR em tempo real. Os resultados demonstraram haver uma forte 
tendência para a sobre-expressão da MGP a nível do mRNA (P= 0.056) em biópsias do 
adenocarcinoma do cólon em comparação com as biópsias de mucosa normal, contrariando 
resultados anteriores indicando uma regulação negativa feste gene. Os resultados aqui 
apresentados são no entanto consistentes com uma elevada expressão da MGP (níveis 
idênticos aqueles que foram observados na mucosa tumoral das amostras dos pacientes com 
adenocarcinoma do colon)  
Tendo em conta estes resultados, procedeu-se então à análise da expressão de fatores de 
transcrição que têm sido descritos na literatura como tendo um papel na regulação da MGP e 
em alguns casos também na tumorigénese. Dos resultados obtidos, constatou-se um aumento 
da expressão dos genes do RUNX2 (p = 0,037) e CCBE1 (p = 0,012) em amostras de 
adenocarcinoma do cólon. Para os genes do FGF2 (p = 0,085) e RARa (p = 0,58) os 
resultados não apresentaram valores estatisticamente significativos. No entanto, verificou-se 
que existia uma correlação de Pearson positiva (r = 0,89, p≤0.0001 para o FGF2 e r = 0,85 , p 
≤0.0001 para o RARa), demonstrando assim uma forte tendência para o aumento da regulação 
simultânea desses fatores de transcrição e da MGP. Em suma, a MGP encontra-se sobre 
expressa nas amostras no adenocarcinoma do cólon, no entanto não é possível estabelecer 
quais os mecanismos de regulação que estão a ser desregulados e se um pior prognóstico 
poderá estar associado a esta desregulação. Para isso, será necessário no futuro realizar i) uma 
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análise mais alargada em número de pacientes, e ii) uma análise mais profunda sobre como 
esses genes interagem entre si. Será também importante analisar quais os efeitos de um 
bloqueio da expressão da MGP na linha celular de adenocarcinoma de cólon, bem como testar 
os efeitos dos fatores de transcrição identificados no promotor da MGP. 
 
Palavras-chave: Adenocarcinoma do cólon; MGP; fatores de transcrição; RUNX2;CCBE1; 
RARα; FGF2  
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1. Introduction 
1.1 Overview on the principles of cell and molecular biology 
In a normal cell, the genomic DNA corresponds to a group of large molecules named 
chromosomes, which are composed by genes and intergenic regions. Genes can either encode: 
1) proteins, which result from sequential transcription and translation processes; or 2) non-
coding RNAs, which exclusively involve transcription of genes (molecules such as ribosomal 
RNAs, transfer RNAs, long non-coding RNAs or microRNAs, result from this process). 
Transcription is a process through which a strand of a segment of DNA from a particular gene 
serves as model for the synthesis of a new strand of RNA. This process is accomplished by 
RNA polymerases. Translation is a process through which an mRNA originates a peptide 
chain and a protein. This process is accomplished by ribosomes and transfer RNAs (which 
transport amino acids into a newly formed peptide chain; Figure 1.1) [1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.1 Translation of mRNA in to a new protein. mRNA polypeptide chain newly synthesized during 
transcription, binds to the ribosomal subunits and tRNA and shifts to the A site where it begins the synthesis of 
the polypeptide chain. Subsequently during the elongation phase the new peptide is synthesized with the help of 
rRNA between A site and P site with de addition of amino acids. Protein synthesis stops when the stop codon 
indicating the end of translation arises A site and the new protein is released from the ribosome into the 
cytoplasm. [1]. (Adapted from http://en.wikibooks.org/wiki/Structural_Biochemistry/Nucleic_Acid/Translation). 
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Eukaryotes, endue several types of RNA polymerases, each one responsible for 
making a particular class of RNA transcript, for instance: RNA polymerase I is entirely 
responsible in generating the transcript that becomes processed into ribosomal RNAs; RNA 
polymerase II is in charge of transcribing all protein-coding genes along with genes such as 
small nuclear RNAs used in RNA processing; RNA polymerase III transcribes all transfer 
RNA genes as well as the 5S component of ribosomal RNA [1]. After transcription, a 
terminal group called cap and a poly-A tail are added to the 5’ and 3’ end of mRNA, 
respectively (both help to regulate mRNA stability). Then RNA processing occurs by excision 
of introns and joining of the exons, in a process involving non-coding RNAs (mostly U1 to 
U6 small nuclear RNAs). Then, 5’ end modifications in the mRNA will enable ribosome 
binding and initiation of protein synthesis [1]. 
Another important process that occurs in cells is DNA replication, which occurs 
during S phase of cell cycle (described in the next section; Figure 1.2). This process involves 
the separation of the DNA strands and breaking the hydrogen bonds by DNA helicase, 
stabilizing and preventing the reattachment of the chain by helix-destabilizing proteins as the 
synthesis of the new chain is not complete, breaks in DNA strands and ligation of them 
though topoisomerases, addition of new nucleotides by DNA polymerase during replication of 
the new strand with the presence of DNA Primase which is responsible for the synthesis of 
the RNA primer which will serve as a template for synthesis of new strands. At the end, the 
presence of DNA ligase are involved in the binding of the new DNA chains recently 
synthesized. At this stage, the majority of spontaneous mutations occur in the genetic material 
in the cell (summarized in table 1.1) [1]).  
 
 
 
 
 
 
 
 
 
 
Table 1.1 Most important types of mutations and their distinctive features (Adapted from essential genetics: a 
genomics perspective [1]). 
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Fortunately, these DNA damages can be repaired through various mechanisms, such 
as, homologous recombination (HR), non-homologous end joining (NHEJ) (responsible for 
repair double-strand breaks (DSB)), base excision repair (BER) and nucleotide excision repair 
(responsible for repair single-strand breaks). NHEJ and HR repair the DNA DSBs induced by 
any mediator capable of splitting the DNA strands [2]. Such agents can comprise endogenous 
factors like reactive oxygen species, but also exogenous factors like UV radiation. HR system 
utilizes a homologous section on a parallel chromatid to correctly repair the DSB. NHEJ takes 
the ends of the damaged DNA molecule together by creation of a synaptic complex resulting 
of combination between two DNA ends, two Ku70/80 and two DNA-PKCS molecules. The 
repair are followed by interruption of ligase IV/XRCC4 complex. BER and NER are also 
important systems to repair single-strand damage, BER is important to shield DNA from the 
endogenous damaging effects made by intracellular metabolites that change DNA base 
structure. The essential enzymes involved in BER system are DNA glycosylases (responsible 
to eliminate different types of damaged bases thru cleavage of an N-glycosidic bond between 
base and deoxyribose of the nucleotide residue). When base is removed, the 
apurinic/apyrimidinic (AP) site is detached by an AP endonuclease or an AP lyase, which 
marks the DNA strand 5’ or 3’ to the AP site. The lasting deoxyribose phosphate residue is 
excised by a phosphodiesterase; the resulting gap is then complete by a repair DNA 
polymerase strand is joined by a DNA ligase. Lastly, NER system responds to harmful effects 
of a multitude single-strand lesions, which can include damage made by environmental 
carcinogenic factors, this system can repair lesions over the entire genome and lesions in the 
synthetized strands that block transcription [2]. When those mutational events provoked by 
mutagens escape repair machineries, they can pass to a daughter cell. If this process occurs in 
germ cells these errors can pass to the progeny, however if these errors occur in a somatic 
cell, they will not be transmitted to the progeny (Figure 1.3). Nevertheless, as described in the 
next section, these errors might originate an aberrant group of cells that eventually may result 
in cancer [3]. As mentioned before, mutations are normally induced by mutagens. These can 
be associated to nutrition, age, sedentary lifestyle and professional occupation [12]. 
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1.2 The Biology of Cancer 
Under normal conditions, nearly all cells of human body have the capacity to divide 
and proliferate in order to balance situations where cell death occurs, either due to mutations 
or because the cell has aged. For this to occur, the cell requires a specialized cellular 
machinery so as to coordinate the entire process that is cell cycle. This machinery involves a 
complex network of multiple exogenous signaling, such as, growth factors or other signaling 
molecules that can be produced by autocrine regulation (produced by the cells), paracrine 
regulation (cell respond according to a stimuli received by neighboring cells interactions) or 
systemic endocrine regulation (cell receives inducements thru circulating hormones) [3]. 
Normally, a cell is in a quiescent phase (G0) performing their structural and biological 
standard functions. When necessary, in presence of a stimuli (e.g. growth factors), phase G1 
is activated and the cells start their cycling. After initiation, the need of growth factors is lost 
when cells pass restriction point R through S phase. At this stage, DNA duplication occurs 
and point mutations, such as insertion or deletion of one or more nucleotides, might occur. As 
described next, in some cases these errors are not properly corrected and the cells somehow 
escape apoptotic pathways, which ultimately may result in cancer. After S phase, the cell 
enters into G2 phase, where the enzymatic machinery necessary to the next phase is produced. 
Figure 1.2 Schematic overview of inherited germ-line versus somatic mutational events. Mutation A 
occurs into the genome of a germ-line cell and pass to other cells in the progeny and so on. On the other hand, 
mutation B only can be passed to lineal descendants of that mutant cell in the body of the parent and cannot be 
transmitted to progeny since this mutation occurs in a somatic cell line genome (Adapted from Biology of 
cancer [57]). 
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After this, the cells enter M phase (Mitosis), where chromosome pairs condensate and are 
distributed equally to the daughter cells. At the end of this phase, daughter cells detached one 
from another and can restart all the cycle process or enter in a quiescent phase (G0) (Figure 
1.3) [3]. 
 
 
 
As mentioned before, when by some reason, one of these steps fail and DNA suffers a 
damage capable of disrupt the well-functioning of this process, cell has a proficient 
mechanism in order to either repair those damages or to induce apoptosis by activation of 
pathways in multiple checkpoints, namely G1 restriction point (R), G1/S and G2/M (figure 
1.3). These checkpoints are recognized by signaling paths and feedback mechanisms that 
guarantee that a cycle phase do not initiate a new phase until the previous one has been 
concluded. If one of these checkpoints fails, genomic instability or apoptotic mechanisms 
ascends and give rise an important step to encourage progression from a normal to a 
malignant cell. This deregulation due to the activation of oncogenes and loss of tumor 
suppressor genes are the major initial step leading to the first stage of tumorigenesis [3]. 
In the beginning of a cell cycle, a cell receives an exogenous signal whether by growth 
factors or molecules of extracellular matrix. Receptors present in the cell membrane integrate 
these signals inside the cell and trigger multiple signaling cascades that are ultimately 
integrated in the nucleus, forcing the cells to initiate the cycle.[4] When the cells are either 1) 
subjected to an exaggerated stimuli by these factors, or 2) those receptors or elements of the 
signaling cascade are defective, or 3) regulators of cell cycle are defective, then the normal 
cells are constantly activated and instigated to an uncontrollable proliferation, promoting the 
occurrence of irreversible mutations in genes. Such process is typically denominated initiation 
Figure 1.3 Cell cycle. Cell initiate its cycling into G1 phase, synthetize DNA in S phase, prepare the necessary 
machinery during G2 phase, enter M phase (where segregation of chromosomes occurs) and form two new cells 
(adapted from the cancer handbook [3]). 
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of tumorigenesis (Figure 1.4 - panel A). In the meantime, during the promotion phase, the 
altered cell and their descendants continues to look normal but its proliferation is much higher 
leading to a stage so called hyperplasia. After a while (time is variable depending on the 
tumor), one million of these altered cells undergo another mutation that decreases more the 
control of cell growth, and the descendants of these cells begin to show abnormal shapes and 
enter into a stage of dysplasia (figure 1.4 - panel B) [4]. These cells and corresponding tissue 
become progressively more aberrant. If this tumor has not broken yet all boundaries between 
tissues, is called in situ adenocarcinoma. This tumor can remain indefinitely contained (figure 
1.4 - panel C) [4]. However, some cells eventually acquire additional mutations that lead to 
genetic modifications and allow the tumor to invade the underlying tissues, i.e. the tumor 
becomes invasive. Some of these cells may be proficient enough to i) escape their matrix, ii) 
invade blood or lymph vessels, iii) escape blood or lymph vessels (extravasion), and iv) 
ultimately invade and colonize new tissues. This process, through which cells from primary 
tumors establish new tumors in other tissues / organs, is denominated tumor metastization, 
which may become deadly by disruption of vital organs (figure 1.4 - panel D) [5]. 
 
 
 
 
 
An important feature of cancer cells is that they are able to create an advantageous 
microenvironment that enables them to proliferate and survive in hostile conditions. Thus, 
cancer cells can: i) recruit other cells (through secretion of cytokines) that will emit important 
stimulatory signals to induce tumor growth; ii) emit their own signals to prevent the immune 
Figure 1.4 Tumorigenesis progression. Cells start to grow uncontrollably, accumulates different types of 
mutations and acquire the capacity to spread to distant sites from the primary tumor. (Adapted from  
https://www.aecc.es/sobreelcancer/cancerenimagenes/Paginas/Cancerenimagenes.aspx) 
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responses; or iii) produce enzymes that will digest the involving matrix and allow cancer cells 
to migrate into surrounding tissues. These are examples of the crosstalk between cancer cells 
and stroma or organisms [5]. Another key characteristic of tumors is their genome instability, 
which can correspond either to microsatellite or chromosome instability. This feature causes 
genetic diversity among tumors and accelerates the tumorigenic process [5].  
In general, any cell of a particular tissue can give rise to a neoplasm (abnormal growth 
of cells). Once these cells loses the ability to control its cell cycle by loss of tumor suppressor 
genes or oncogenes, it gains the ability to divide abnormally resulting in a tumor mass that 
can either be: i) benign, characterized by a slow and typically encapsulated cell growth; or ii) 
evolve to malignancy, characterized by a more rapid cell proliferation and ability to invade 
surrounding tissues, which may give rise to secondary tumors. According to their cellular 
origin, tumors can be classified into carcinomas and melanomas (derived from epithelial 
cells), sarcomas (arise from mesenchymal tissues), retinoblastomas, neuroblastomas and 
glioblastomas (derived from cells in the ocular retina, neurons and neural glia) [2]. 
 
 
1.3 Colon adenocarcinoma as a genetic disorder 
Colon adenocarcinoma (CAC) is the second most frequent cancer in Portugal, 
representing 10% of all tumors in both genders. Although CAC diagnosis is usually 
performed in a symptomatic phase, with a level of progression around 10 years, the prognosis 
remains relatively reserved, presenting an overall survival rate after 5 years slightly above 
50% for both men and women. Indeed, every day in Portugal around 9 to 10 patients die with 
colon and rectum adenocarcinomas, and similar numbers are found worldwide [6]. In this 
regard, population-wide screening and detection of CAC in an asymptomatic stage is the main 
strategy that can change this situation in order to diminish mortality [6]. Indeed, according to 
ROR-Sul (Oncological Registration in South of Portugal; 19) data, 81% male and 78% female 
patients under 60 years of age were diagnosed with CAC [8]. 
At a histological and molecular level, CAC is the best studied cancer type, which in 
part results from its insidious progression and easy visualization and separation of different 
stages [2]. In figure 1.5 the main molecular events associated tumorigenic steps colon 
adenocarcinoma (initiation, progression and invasion) are depicted 
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Figure 1.5 Colon adenocarcinoma model proposed by Fearon and Vogelstein. Multistage progression of 
colon adenocarcinoma, where mutations on the APC tumor suppressor normally are considered to be the initial 
event, followed by the successive accumulation of other epigenetic and genetic changes (loss of deleted colon 
cancer gene (DCC) or mutated colon cancer (MCC) and p53) that possibly can result in the progression from a 
normal cell to a metastatic tumor (adapted from Molecular biology of cancer [4]). 
 
 
From an histological and pathological point of view, colon adenocarcionomas are 
classified according to a standardized system that characterizes how far tumor has progressed: 
if it has spread to other areas (T), if it is already associated with the lymphatic system (N), and 
how distant it have spread and metastasized to other organs (M; most commonly to lungs and 
liver. This classification, the TNM staging, is the most in used system for tumors 
characterization, and is also known as American Joint Committee on Cancer (AJCC) [9]. 
Nevertheless there are other classification systems, such as Dukes and Astler-Coller systems 
[9]. 
 
 
1.3.1 Sporadic colon adenocarcinomas 
More than 95% of colon adenocarcinomas are sporadic, which means that they are 
caused by point mutations that occur and are perpetuated in somatic cells of colon epithelium. 
Generally, these tumors are associated with early mutational events and the progression of 
age, appearing at a mean age of 70 years and can be caused by external factors inherent to the 
lifestyle of the patient [2]. Indeed, the contact to a variability of natural and artificial 
mutagens in the environment is believed to account for up to two-thirds of cancer mortality 
(depending the cancer type) [4]. In general, these mutagens can be classified as physical (e.g. 
radiation), chemical (e.g. hormones and organic combustion products) and biological 
mutagens (e.g. viral and bacterial infections). Factors like these are present in the day life of 
an individual and are strongly associated with the rising of spontaneous colon 
adenocarcinomas [12]. 
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One the most important biomarkers of adenocarcinomas and always considered in 
pathological exams is K-Ras. This gene belongs to the Ras family and is a small molecular 
weight protein, post-translationally modified by the addition of a farnasyl fatty acid moiety to 
the C-terminus. This post-translational modification is essential for the activity of Ras 
oncogenes, and therefore it has become an important target for the development of therapeutic 
strategies [10]. This protein binds equally to guanosine 5’-triphosphate (GTP) and guanosine 
5’-diphosphate (GDP) in a reversible way. When activated, Ras bounds to GTP and is capable 
to initiate signals through mitogen-induced and stress-induced pathways, regulating gene 
transcription (required for cell growth) and proliferation. Signals like this are typically 
promoted by activation of receptors such as the epidermal growth factor receptor (EGFR) 
[10]. Thus K-Ras or EGFR mutations are known to result in a constitutive activation of these 
pathways, leading to overstimulation of cell proliferation and ultimately to cancer. For this 
reason, these genes are considered to be good biomarkers and therapeutic targets in cancer, 
more specifically in colon adenocarcinoma [10]. However, it is important to determine and 
distinguish these changes since it can influence the type of treatment to follow. For example, 
targeted treatments against EGFR are not as effective if the patients carry K-Ras mutations. 
Other crucial genes in colon adenocarcinoma are the APC, the MSH2 (acts in the 
mismatch DNA repair system) and p53 (activated in response to cellular stress). These are 
tumor suppressor genes, which are responsible to inhibit cell growth directly or indirectly. 
The tumor suppressor genes that promote apoptosis of a cell directly are called “gatekeepers” 
[4]. 
 
 
1.3.2. Inheritance of CAC predisposition 
Familial adenomatous polyposis coli (FAP) 
There are some morphological and molecular evidences that colon adecarcinoma 
develops through several precursor stages (figure 1.5). The initial identifiable pre-neoplastic 
modifications results in hyperplastic or dysplastic adenomatous polyps precursors of 
adenocarcinomas. Polyps are regularly found as single benign tumor distended into the lumen 
of the large intestine and consist of a relatively disorganized epithelium. In the familial 
adenomatous polyposis coli syndrome (FAP), multiple polyps are found and it is strongly 
associated with the risk of colon adenocarcinomas [11]. Patients with FAP tend to develop 
hundreds of adenomatous polyps in an early age (~40 years old) that are present alongside the 
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entire gastrointestinal track. Different phenotypes are also underlined to this inherited 
syndrome, for instance, Attenuated FAP (AFAP; differs from normal FAP in less number of 
polyps displayed), Congenital hypertrophy of the retinal pigment epithelium (CHRPE; the 
early detection of this variant could be an indicative of FAP before the appearance of polyps) 
and Gardner’s syndrome (associated with benign osteoid tumors and skin cysts). With the 
intention of diminish the risk of colon cancer associated with this syndrome, the advised 
therapeutic to follow involves a prophylactic colectomy or a proctocolectomy [11]. This 
syndrome is characterized by being inherited in an autosomal-dominant way, with an 
inherited partial or total deletion of an APC allele. When the loss of the other functional copy 
occurs, this loss is denominated loss of heterozigosity (LOH) [11]. This situation is the major 
example of inherited colon adenocarcinomas. However, this mutation is also known to occur 
in sporadic colon adenocarcinomas during a former stage of colon adenocarcinoma 
tumorogenesis also with a LOH association. As a result, constitutive activation of oncogene c-
myc occurs (through a difficult assembly of protein-protein interactions). APC can also 
interact with other cellular proteins, including the oncogene β-catenin. Loss of APC 
ultimately leads to stabilization of β-catenin and activation of Tcf-mediated transcription 
(anti-apoptotic) [11]. Besides the regulation of proliferation and apoptosis, APC is important 
to cellular adhesion and cytoskeletal integrity, maintenance of intestinal cell migration and 
regulation of c-myc and cyclin D1 expression levels in G1/S transition phase [11]. 
 
Hereditary non-polyposis colon carcinoma (HNPCC) 
The hereditary non-polyposis colon carcinoma syndrome (HNPCC) or Lynch 
syndrome is known to be more frequent than FAP syndrome and usually found in an upper 
zone of the colon comparatively with FAP syndrome and sporadic cases of colon 
adenocarcinoma. The major difference between HNPCC and FAP syndrome is the type of 
mutations found. For example, nearly all the genetic modifications results from base 
exchanges, small deletions or insertions of base pairs and point mutations, whereas 
chromosomal modifications are occasional. The mutations founded associated to this 
syndrome are simply detected in microsatellite sequences that can be the repetition of one, 
two or three nucleotides. Once these microsatellites are greatly polymorphic, individuals tend 
to be heterozygous. These microsatellites can be used as allelic markers or to track 
chromosomal recombination and loss in carcinogenic cells [13]. 
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Increase or reduction of a microsatellite repeat is denominated as microsatellite 
instability (MSI). This phenomenon leads to inactivation of genes involved in mismatch 
repair mechanisms. Several proteins present in this mechanism are responsible for the first 
detection of these mismatches during DNA replication. Important examples are MSH2 / 
MSH6 and MSH3 / MSH6 heterodimers, MLH1, hPMS1 and hPMS2. Patients with HNPCC 
carrying mutations in one gene (MSH2 or MLH1) that encodes for this repair mechanism 
have more probability of developing colon cancer. Again, in these cases the inactivation of 
the second copy has to occur in order for the repair system to be compromised (8).  Curiously, 
this MSI phenotype can also be observed in sporadic cancers in patients without a family 
history. In some cases, the inactivation of MLH1 gene is permitted by promoter 
hypermethylation, increasing the risk of mutations in other genes. Hence, HNPCC cancers 
can embrace the same gene mutations that prevail in other colon adenocarcinomas, e.g. APC, 
p53, K-Ras or β-catenin. Nonetheless, some genes are privileged mutation targets in colon 
cancers rising in HNPCC syndrome and sporadic MSI compared to other colon cancers forms 
[13]. 
 
 
1.4 Matrix Gla Protein (MGP) 
Human MGP is a 10kDa protein dependent of vitamin K metabolism, contains84 
amino acid residues, is primary structure includes a signal peptide, a phosphorylation domain, 
and a γ-carboxylase recognition site. Additionally, MGP contains five residues of γ-
carboxylated glutamic acid (Gla) residues that are converted from Glu to Gla residues by γ-
glutamyl carboxylase enzyme, dependent of vitamin K, via a posttranslational modification. 
This protein was initially isolated from extracts of demineralized bovine bone matrix and was 
later isolated from cartilage [14][15]. MGP is found in a wide range of non-calcified tissues, 
such as lungs, kidneys and heart [16] and despite this extensive tissue distribution, only 
cartilage and bone can gather significant levels of MGP in the extracellular matrix [16].  
 
1.5 MGP function 
MGP has been described to have an important role on mineralization inhibition and 
chondrocytes maturation [17]. Genetic studies have shown that MGP null mice die around 
two months of age as a result of excessive abnormal calcification of their arteries, leading to 
blood vessel rupture, clarifying the role of MGP as a physiological inhibitor of calcification 
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[18]. Lack of MGP results in transdifferentiation of aortic smooth muscle cells to 
osteochondrogenic lineage, possibly due to release of BMP2/4 from MGP dependent 
functional inhibition. MGP has also been involved in cell differentiation as suggested by 
Yagami et al (1999) [19]as well as in proliferation (reviewed by [13]).  Mutations found in 
human MGP gene have been associated with abnormal calcification of cartilage in Keutel 
syndrome (5), pathological conditions related to atherosclerosis (vascular calcification) and a 
wide range of cancers [20][21][11].  
 
 
1.6 Regulation of MGP gene expression 
As already mentioned, known sequences of vitamin K-dependent proteins in 
vertebrates have a signal peptide followed by a transmembrane recognition site of γ-
carboxylation, and a domain containing Gla residues in each of these regions, which in MGP 
corresponds to a single exon. The human MGP gene, localized in chromosome 12, has been 
cloned and sequenced [22] and until recently, was thought to give rise to a single transcript 
containing four exons. However, recent evidences show that more than one variant can arise 
from this gene. Indeed, a new MGP variant (E5; accession number: NM_001190839.1) 
containing five exons was shown to occur (Figure 1.6) [13]. 
 
 
 
 
 
 
 
 
 
As depicted in figure 1.6 this variant comprises a new sequence with 75bp encoding a 
new epitope with 25 amino acids. The function of MGP E5 remains unclear, and therefore 
exploring its expression in systems where MGP was previously detected will be crucial to 
understand is role. 
The promoter of MGP gene has been investigated in previous studies. In this regard, 
many transcription factors putative binding sites have been reported, but only a few were 
actually shown to be functional. 
Figure 1.6 Alternative splicing in transcript variant E4. Schematic representation of MGP splice variants. 
The sizes of exons (1cm=100bp) and introns (1cm=300bp). Solid boxes indicate the coding regions and open 
boxes indicate untranslated sequences. 
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Thus, previous analysis of human MGP gene promoter revealed the existence of 
several consensus structural motifs apparently important for putative binding of the typical 
TATA and CAAT boxes, of AP1 and AP2 transcription factors and of metal-responsive 
elements. This analysis also revealed the existence of two polymorphisms, i.e. G-7A and T-
138C, in a region apparently essential for transcription activity (as determined in vitro). Since 
the second polymorphism was associated to AP-1 binding site it was postulated that it would 
influence AP1 complex binding to MGP promoter and alter MGP gene expression. Given the 
previous association of MGP to calcification in arteries, it was hypothesized that this 
polymorphism could be implicated in higher susceptibility to atherosclerosis and aortic valve 
stenosis [23].  
In other studies, specific binding sites for retinoic acid (RA) and vitamin D (VD) 
receptors were identified in MGP promoter. However, the effects of these regulatory elements 
were far from being consensual. Regarding RA, depending on the cell lines (fibroblasts, 
chondrocytes, osteoblasts, human osteosarcoma cells MG-63, teleost fish and MCF-7) it was 
shown to either induce or repress MGP gene expression [24][25]. In the case of VD, in some 
cell types (human osteosarcoma cells MG-63) it was shown to up-regulate MGP gene 
expression, while in other (fibroblasts, human osteoblast and chondrocytes), it did not 
promote significant changes unless it was administered in combination with RA. In the latter 
case, VD attenuated the positive regulation promoted by RA [26][27][28].While discrepancies 
found for RA may be explained by the presence of different elements in the respective 
receivers (i.e. cell lines), the antagonism found between RA and VD may be explained by the 
potential formation of heterodimers between RA and VD receptors, which should decrease 
the amount of available RA receptors [28]. 
Another transcription factor that was shown to be able to regulate MGP gene 
expression is Runx2, although this was only demonstrated in Xenopus laevis 
[10].Interestingly, in Xenopus laevis, two functional promoters (proximal and distal) were 
identified in MGP gene, and both shown to be regulated by Runx2. This regulation apparently 
involved Runx2 binding to three specific regions, through which it was shown to induce 
transcription activity. Additionally, a fourth Runx2 binding site was found in the distal 
promoter but with a putative repressive action in gene transcription. This suggested that 
Runx2 may have a dual effect on MGP expression depending on which site it binds [10], in 
addition to AP1, RA and VD (in addition with RA) as promoters of MGP transcriptional 
regulators. 
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1.7 MGP in Cancer 
Despite what is known about the regulation of MGP in bone and cartilage, evidences 
have demonstrated the existence of a regulatory effect in breast cancer, colon carcinomas and 
glioblastomas [11][15][24][16]. Still, little is known of how MGP acts during tumorigenisis 
pathways, how deregulated expression is related to different kind of tumors. Both in breast 
cancer and glioblastomas it was demonstrated a relationship between the upregulation of 
MGP and the poor prognosis displayed [11][16]. MGP has been independently discovered by 
differential cDNA screening as a gene which is overexpressed by human breast and urogenital 
tumor tissue and cell lines, but a downregulated expression was observed to be correlated 
with an unfavorable clinical status such as a poor differentiated state, a larger tumor size, and 
lymph node metastasis [29]. In another study it was reported the putative value of MGP as a 
biomarker for poor prognosis in patients with breast cancer. Results showed that in patients 
exhibiting a poor prognosis MGP mRNA expression was up-regulated, which led to suggest 
that MGP have the potential to serve as a prognostic indicator of the disease, however, no 
correlation was established between protein levels and overall survival rate [11]. In colon 
adenocarcinoma the expression levels found demonstrate the inverse situation [15], levels of 
mRNA for MGP were found to be downregulated in colorectal tumor tissues as compared 
with their paired normal tissues [15]. MGP has also been found to be overexpressed in 
ovarian cancer [30], in prostate epithelial cells undergoing apoptosis [31] and in vascular 
smooth muscle cells undergoing dedifferentiation in cell culture [32]. These results suggest 
that additional players must be involved in MGP regulation process and more work needs to 
be developed in order to understand the involvement of MGP in tumorigenesis.  
Since the function of MGP and its variants are presently unknown in CAC, it is 
important to try to understand if MGP along with is putative transcriptional regulators may be 
associated with the progression of tumorigenisis in sporadic or inherited forms of CAC and if 
it can be consider as a possible biomarker for future therapeutics. 
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1.8 Main Aims 
In recent years, we have assisted to an improvement of general methods for diagnosis and 
mass screening of colon adenocarcinomas. This resulted not only in an increase in the number 
of tumors detected at an early stage, but also in a higher life expectance of these patients 
(average survival rate after 5 years of ~50%). However, despite an effort to allow all patients 
to have access to routine exams to detect colon adenocarcinomas, in many cases these tumors 
are still found in advanced stages. In that sense, it is vital to search for new biomarkers and 
therapeutic targets in colon cancer. With the colon adenocarcinoma being the second most 
frequent cancer in Portugal (and worldwide), representing 10% of total tumors in both 
genders, is urgent to find such new biomarkers. MGP, a protein that was previously 
associated to physiological and pathological inhibition of calcification of cartilage and 
arteries, was shown to be involved in many cancer types. Although the specific involvement 
of MGP in colon adenocarcinoma was previously addressed, is specific role in this tumor and 
association to different stages was far from being established. In this regard, the main aims of 
this research were to: 
1) Investigate MGP dysregulation in colon adenocarcinomas; 
2) Identify specific tumor stages where MGP gene becomes deregulated; 
3) Identify gene regulatory mechanisms associated with MGP deregulation in colon 
adenocarcinomas. 
To accomplish these objectives, samples from tumoral and adjacent normal mucosa of 
patients with colon adenocarcinoma were obtained through collaboration with 
Gastroenterology Department of Hospital de Faro. RNA was extracted from these samples 
and further used to analyze the expression of MGP and transcription factors. 
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2. Materials and Methods 
2.1 Patient selection and collection of tissue samples 
Tissue samples were dissected directly from tumor tissue (MT) and 5 cm away from 
tumors (control samples, MN) of 45 patients with colon adenocarcinomas during 
colonoscopies exams at Hospital Central de Faro (Gastroenterology Service, Dr. Paulo 
Caldeira). Samples were collected to microcentrifuge tubes containing 1ml RNAlater (Sigma-
Aldrich) and maintained at 4ºC up to 24 hours. From these patients, 11 were male and 9 were 
female, and their ages ranged from 36-92 (Table 3.1 Chapter 3). Clinical stage of the tumor 
was previously determined according to TNM Staging criteria then confirmed by a pathology 
service. These samples were obtained with full knowledge of the patients and approved by 
local ethics commission. 
 
 
2.2 RNA Extraction 
The method used for total RNA extraction was based on that described by 
Chomczynski and Sacchi [25]. Briefly, tissues were homogenized in 1 ml Solution D (see 
appendix I for solution composition) using a 1ml syringe with 20 gauge needle. This process 
was also used to shear genomic DNA. Then, each sample was mixed with 100 μl of 2M 
NaOAc (Sodium Acetate, pH 4.0), 1 ml of phenol (pH 4.3±0.2) (Sigma-Aldrich) and 200 μl 
of CIAA (Chloroform:Isoamyl alcohol) (see appendix II for the solution composition), and 
incubated for 15 minutes on ice. Samples were centrifuged for 15 minutes at 10,000xg, 4ºC. 
Aqueous upper layer was transferred to a new microcentrifuge tube containing 1 ml of 100% 
isopropanol, mixed and stored for 1 hour at -20ºC, for RNA precipitation. Then, samples were 
centrifuged for 30 minutes at 10 000xg (4ºC) and RNA pellets re-suspended with 500 µl of 
solution D and transferred to a clean microcentrifuge tube containing 500 µl of 100% 
isopropanol. RNA was again precipitated (1 hour at -20ºC) and centrifuged for 15 minutes at 
20 000xg, 4ºC. Pellets containing total RNA, were washed with 500µl of ice-cold 75% 
ethanol, left air dry for 1 minute and dissolved in 30µl of H2O (Sigma). 
Quality and quantity of RNA was assessed by spectrophotometry (using Nanodrop 
ND-1000; Thermo Scientific), through reading the absorbance of each sample at 230, 260 and 
280 nm, and determining the ratios at 260/230 nm and 260/280 nm. Additionally, each sample 
(1µg) was analyzed in 2% TAE agarose gel electrophoresis for size-separation and detection 
of most abundant ribosomal RNAs. Finally, samples were stored at -80º C for later use. 
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2.3 Synthesis of cDNA by Reverse Transcriptase reaction 
Total RNA (1µg) was treated with RQ1 DNase (1U for each 1µg of RNA; Promega) 
according to manufacturer’s instructions. After 30 minutes incubation at 37ºC, reaction was 
stopped by supplementing RQ1 stop solution (Promega) and incubating 10 minutes at 65ºC. 
Then, RNA was purified using the High Pure RNA isolation kit (Roche), according to 
manufacturer instructions. For further analysis of mRNAs, samples were used to synthesize 
cDNA using the Moloney-murine leukemia virus (M-MLV) reverse transcriptase (200U/µl, 
Invitogen), according to manufacturer protocol. Briefly, 500 ng of total RNA were 
supplemented with 0,4µl oligo(dT)12-18 Universal oligonucleotide (500µg/ml; Sigma-Aldrich; 
see Table X), 1µl dNTP’s (10mM, Invitrogen) and water (Sigma-Aldrich) for a total volume 
of 12µl. This mixture was incubated during 5 minutes at 65ºC, and then supplemented with 
4µl of First Strand buffer (5x, Invitogen), 2µl DTT (0,1M, Invitrogen), 1µl RNaseOUT 
(40U/µ, Invitrogen) and 1µl of M-MLV reverse transcriptase. Reverse transcription continued 
for 50 minutes at 37ºC. Finally, samples were incubated during 15 minutes at 70ºC to 
inactivate the reaction enzymes and denature cDNA.  
 
  
2.4 Real-Time Reverse Transcriptase Quantitative Polymerase Chain Reaction PCR 
(RT-qPCR) 
cDNA samples were used as template for real-time PCR analysis of mRNA expression 
using specific primers listed in table I.1 (see appendix I). To determine mRNA expression, 
2µl of cDNA (1:10 dilution) were mixed with 10µl of SsoFastTM Eva Green Mix (BioRad), 
0.6µl of each specific primer (10µM) and water (up to 20µl). PCR amplifications were 
performed in a StepOnePlus Thermoycler (Applied Biosystems) using the following 
conditions: i) denaturation and polymerase activation at 95ºC during 30 seconds; ii) 40 cycles 
of denaturation (5 seconds at 95ºC) and annealing/elongation (30 seconds at 57ºC); iii) melt 
curve (65ºC-95ºC) for determination of melting point. As negative control, PCR amplification 
were performed using water as template. Relative expression was determined using the ΔΔCt 
method. Threshold cycles obtained for each analyzed gene were normalized using GADPH 
(Glyceraldehyde-3-phosphate Dehydrogenase) housekeeping gene. 
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2.5 Cell line and Culture 
HT29 human colon adenocarcinoma cell line was cultured in DMEM (Dulbecco’s 
Modified Eagle Medium; Gibco, Life Technologies) supplemented with 10% fetal bovine 
serum (FBS), 1% L-Glutamine and 1% Pen Strep (Penicillin/Streptomycin mixture; Life 
Technologies), and maintained at 37ºC and 5% CO2. Cells were subdivided 1:8 twice a week. 
 
 
2.6 RNA interference assays 
For RNA interference of MGP, HT-29 cells were either seeded in 6-well plates 
(2.5x105 cells/well) or 96-well plates (1.0x104 cells/well), and mixed with appropriate 
quantity of Lipofectamine RNAIMAX reagent (Invitrogen) and small interfering RNAs 
(Stealth siRNAs, Invitrogen), according to manufacturer instructions. Regarding the use of 
siRNAs, one was directed against MGP and the other was identical to the first one but 
containing mismatch nucleotides (used as negative control; Invitrogen). To verify the success 
of RNA interference experiment, qRT-PCR and western blot analysis were performed using 
extracts from cells seeded and transfected in 6-well plates (72h after transfection). Cells 
transfected in 96-well plates were used for proliferation assays, described next. 
 
 
2.7 Proliferation assay 
MTS (3-(4,5dimethylthiazol-2-yl)-5-(carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-
tetrazolium reagent (Promega) was used to assay the number of viable cells in culture. 
Basically, viable cells contain dehydrogenase enzymes that will convert MTS into formazan, 
which absorbs at 450 nm. Since different cell lines are metabolically distinct, this assay had to 
be optimized for HT-29 cells. For that, HT-29 cells were seeded in 96-well plates (1x104 
cells/well) and incubated for 12-16 hours at 37ºC / 5% CO2. Then, MTS / PMS (activating 
reagent) mix was added to the cells as indicated by the manufacturer (Applichem). 
Absorbance at 450 nm (formazan) and 650 nm (background correction) was read after 2, 3, 4 
and 5 hours. Linearity of this reaction was between 3 and 5 hours, and therefore optimal time 
of reagent incubation was considered to be at 4 hours. Then, these conditions were used to 
evaluate cell proliferation after transfecting HT-29 cells with siRNAs. Briefly, 24, 48 and 72 
hours after transfection, HT-29 cells transfection media was replaced by new media 
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containing MTS / PMS. Then cells were incubated during 4h at 37ºC / 5%CO2 and 
absorbance was read in a Synergy4 microplate reader (Biotek). 
 
 
2.8 Western Blot assays 
In order to prepare extracts from HT.29 cultures, cells were first rinsed (3X) with 
phosphate-buffered saline (PBS). After 50µl lysis buffer supplemented with complete 1x 
concentration (protease inhibitor, Roche. See appendix II for solutions composition) was 
added to culture and cells scrapped from plate surface using a cell scrapper (Sartstedt). Then, 
extracted cells were transferred into a microcentrifge tube and centrifuged during 15 minutes, 
at 15,000G and 4ºC. Supernatant was transferred into a new microcentrifuge tube (2-3 μl of 
this extracts were transferred into another microcentrifuge tube for further protein 
quantification) and mixed 1:4 with Sample Buffer 4x (SB4X; see appendix II for solutions 
composition). This mix was heated at 100ºC, 5 minutes, for protein denaturation, preceding 
SDS-PAGE. Simultaneously, pellet was re-suspended in the same volume, mixed SB4X and 
denatured for 5 minutes and 100ºC. At this stage, supernatants and pellets could be stored at -
20ºC. Protein was quantified in cell extracts using the Quick Start™ Bradford Protein Assay 
(Bio-Rad), according to manufacturer’s instructions. Briefly, the reagent was diluted 1:5 in 
water and filtered in 0.45μm pore filters. Subsequently, appropriate amounts (in 10 μl 
volume) of samples and protein standards (Bovine Serum Albumin - BSA) were added to 
each well of a 96-well plate, and supplemented with 200 μl of reagent. After 10 minutes 
incubation, absorbance was read at 595nm in Synergy4 microplate reader (Biotek). 
After determining protein concentrations, equal amounts of protein samples were 
loaded into an SDS-PAGE gel (NuPAGE® MES 4-12%Tris-Acetate 3-8%; Invitrogen) and 
size fractioned using an appropriate running buffer (See appendix II for solutions 
composition) at 160V. Samples were then transferred onto a PVDF membrane 
(polyvinylidene fluoride membrane, Immobilon®-P, Millipore) using transfer buffer (See 
appendix II for solutions composition) during one hour at 30V. Finally, membrane was 
autoclaved to cross-link proteins and stored for future WB analysis. 
For western blot analysis membranes were first incubated with blocking solution (See 
appendix II for solution composition) during two hours at RT. Then, membrane was 
incubated with primary antibody against MGP (rabbit IgG; ProteinTech) diluted 1:1500 in 
blocking solution during one hour at RT. After serial washes with PBST (2X 5 minutes) and 
salts solution (2X 5 minutes; see appendix II for solution composition), membrane was again 
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incubated with blocking solution for 15 minutes. Membrane was after incubated with 
secondary antibody anti-Rabbit IgG with horseradish peroxidase conjugate (Sigma) diluted 
(1:30000) in blocking solution during one hour at RT. To conclude, new serial washes were 
performed: i) 2X 5 minutes with PBST, ii) 1X 10 minutes with Salts solution, iii) 3X 5 
minutes with PBST, and iv) 1X 1 minute with PBS. To reveal the signal, membranes were 
incubated with chemiluminescence substrate (Western Lightning® Plus-ECL, PerkinElmer, 
Inc.), according to the manufacturer instructions. Corresponding images were obtained using 
the ImageQuant LAS500 (GE Healthcare Life Sciences).  
For normalization of the western blot, β-actin (santa-cruz, Biotechnology) was used as 
a housekeeping, fowling the previous method described for membrane incubation. Initially an 
incubation with primary antibody against β-actin diluted (1:15000) followed by an incubation 
with the secondary antibody mouse igG with horseradish peroxidase conjugate (Sigma) 
diluted (1:30000). 
 
 
2.9 Statistical analysis 
The results of qRT-PCR were analyzed by paired t-test to determine the significance 
of the difference between expressions of MGP in the paired normal and tumoral tissue 
samples obtained from patients. Data are presented as mean of standard deviation from 
independent replicates and the statistical significance of the results was obtained using the 
GraphPad prism 5.00 Software, Inc., La Jolla, CA, USA and IBM SPSS Statistics 22 
Software, (Armonk, NY, USA). Probability under 5% (P≤0.05) was considered to be 
significant. 
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3. Results and Discussion 
3.1 Clinical characteristics and MGP gene expression in patients with colon 
adenocarcinoma 
Over the past years, the important role of MGP as a physiological inhibitor of 
mineralization has been described in several systems [26] including mammals [14], [27], [28], 
amphibians [29] and bony and cartilaginous fish [19] [30] [31].  In addition, MGP has been 
shown to be expressed in several other organs, including lung, heart, kidney [32] [33] [34], 
vascular system [35], and in the intestine [15], but its function in these systems and 
mechanisms of action remains largely unknown. MGP has been also associated with several 
pathological conditions, such as ectopic calcification in β-thalassemia [36], atherosclerosis 
[37] , chronic kidney disease [38] and several other cancers, including breast carcinoma [37] 
[39] and glioblastoma [16]. Interestingly, despite being one of the most common and well-
described cancer types, the association of MGP to colon adenocarcinoma has been roughly 
established and so far poorly investigated [15]. Recently, a new variant of MGP (E5) has been 
published with a new exon compared with the existent variant E4 with four exons probably 
due to the existence of an alternative splicing in exon two. It is known that this new variant is 
expressed in human some particular tissue, however, its function related with tumorigenic or 
other types of molecular mechanism remains unknown to the best of our knowledge.  
In order to explore the presence of both MGP variants (E4 and E5) in colon 
adenocarcinomas, we performed qRT-PCR analysis using RNA samples collected from 20 
patients selected after clinical and pathological characterization and specific set of primers for 
both variants (E4 Forward1/Rev5 and E5 Forward1/Rev4; see Appendix I, Table I.1),. This 
group of patients was characterized according to age, gender, tumor location, tumor 
differentiation, K-Ras mutations, tumor staging, family history (for possible association with 
genetic syndromes) or association to other diseases (including other tumors; see Tables 3.1 
and 3.2). All these characteristics were considered as putative factors that could influence in 
vivo MGP regulation. 
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Table 3.1 Clinical characterization of patients and MGP relative variation between tissues samples 
 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
According to GLOBOCAN (International Agency for research on cancer World 
Health Organization) in 2012 the incidence of colon adenocarcinoma in the world was 10.0 % 
and 9.2% in male and female population, respectively. The age-standardised death rate (ASR) 
was 10.0 deaths per 100.000 male population, and 6.9 deaths per 100.00 female population.  
Nowadays with the advancement of biomedical research and the improving of detection 
methods, the possibility of finding adenocarcinomas at an earlier stage was increased.  
Although colon adenocarcinoma is present among the top five cancers with higher mortality 
rates for both sexes worldwide, it is possible to see an increase in the survival rate of patients 
5 years after diagnosis of the tumor, at a global level. 
In Portugal, the numbers presented by ROR-Sul (Registo oncológico do Sul) show that 
81% of men and 78% of women diagnosed with colon adenocarcinoma have over 60 years-
old. Regarding rectum adenocarcinoma,it was considered the sixth most frequent 
adenocarcinoma in both sexes, in South region, representing about 6% and 4.5% of total cases 
diagnosed in male and female respectively, with two thirds of the cases diagnosed after the 
age of 60 years-old. For this type of tumor, the population covered by ROR-Sul, have a higher 
risk for developing rectum adenocarcinoma compared with the incidence rates offered by 
other European countries. As previously described in Chapter I, intestine (colon and rectum) 
tumors may be originated from hereditary syndromes such as familial adenomatous polyposis 
caused by a mutation in APC gene (representing less than 1% of the population and appears 
around the age of 40 years-old) or by causes not associated with polyposis as Lynch 
syndrome, that results from a mutation in the DNA repair genes, representing about 2% of all 
cases of colon and rectum cancers in Portuguese population. 
According to the ROR-Sul the 5 year survival rate for colon adenocarcinoma patients 
was 53% and 58% for male and female, respectively, while in rectum adenocarcinoma was 
54% and 55% for male and female respectively. 
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The average age of patients analyzed was 71 years (±13). This finding was in 
settlement with a presumed association of most patients with sporadic colon adenocarcinoma 
(unrelated to genetic syndrome). Indeed, most sporadic cases appear after age of 50 years-old 
(44), as opposed too much earlier appearance in cases associated to genetic syndromes (e.g. 
APC, Lynch syndrome, tendency to appear under age of 40 years old).  
Between the total number of patients analyzed (n = 20), 55% were male and 45% 
female. Based on histology, 55% were well differentiated, 40% moderately differentiated and 
only 5% of the patients had a poor differentiation tumor. 
It is known that the use of staging tumor progression is the main asset for the 
therapeutic to follow, however, tumor location, the type of mutation that led to its progression 
are also important, in fact, a tumor located in the rectum, together with the fact of being in a 
more advanced stage has a worse prognosis relative to patients with an adenocarcinoma 
limited to colon with a poor differentiation [2]. According, in our study (Table 3.1), we 
Table 3.2 Patients and tissues samples distributed by technical features 
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observed that in 45% of cases with adenocarcinoma, located in rectum, the prognosis for most 
patients is reserved and with a higher staging. KRAS gene mutations influence the therapeutic 
to apply to the patient, it is important to apply a specific treatment taking into account the 
individual characteristics of the patient, instead applying therapeutic for colon 
adenocarcinomas in a general way. As described earlier, mutations in the KRAS gene 
constantly activate oncogenic signaling pathways that promote cell cycle progression, by 
itself therapies based on the inhibition of this signaling pathway (anti-EGFR) are not very 
effective.  
According to clinical information obtained (Table 3.2), 6% of the patients analyzed 
have KRAS mutations indicating that the treatment with anti-EGFR will not be very effective. 
These data are in agreement with a previously published data on the incidence of KRAS 
mutations in Asian population, which found that the appearance of such mutations was not 
related to the patient's age [2]. Nevertheless, is necessary to keep in mind that there is an 
epidemiological variation between populations and factors that lead to the emergence of such 
mutations in Asian population may not be the same as for the European population, in this 
particular case, the Portuguese population (Algarve region) and incidence of this type of 
mutations related with tumor location may vary. In fact, there was no obvious association 
between MGP relative variation and KRAS mutations, or at least KRAS mutations were not 
significantly associated to higher levels of MGP expression. In general, during this analysis it 
was not possible to establish a correlation between the levels of MGP expression (and 
respective variation between tumoral versus normal mucosa) (results described below) and 
any particular characteristics of the patients, including tumor staging, age or gender (Table 
3.1). 
After characterizing the group of patients, samples collected from normal (adjacent to 
tumor) and tumor intestinal mucosa were used for RNA extraction and subsequent qPCR 
analysis of MGP variants expression.  Throughout the process of sampling, samples were 
initially stored in RNAlater and kept at 20ºC until a week before the RNA extraction was 
made. After extraction of RNA from the first set of sampling (n = 10), expression analysis for 
the genes of interest was made, however it was found through RNA electrophoresis and high 
CT’s values presented by housekeeping genes, that RNA integrity was compromised and 
therefore would not be possible to use those samples for further analysis (data not shown). To 
overcome the effects of storage of samples for RNA extraction, since high-quality RNA is the 
first, and often the most critical, step in performing real-time PCR, we changed the 
procedures of storage and processing of the samples, for maximizing the yield and quality of 
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sample. Samples collected in RNAlater, was stored at 4 ° C up to 24h at most and then 
transported to the laboratory on ice to minimize RNA degradation, and immediately 
processed for RNA extraction. For the RNA extraction process it was also necessary to 
optimize the first step. To each sample we added 1mL solution D (instead of 500µl), to 
minimize the contamination of RNA with phenol. The rest of RNA extraction protocol was 
the same as described in the section of methods and materials (section 2.2 RNA extraction). 
Levels of MGP gene expression were determined in the 20 patients, by real-time 
qPCR, and normalized using GADPH as housekeeping gene. For all samples analyzed, the 
results showed an inexistent expression of variant E5 (results not shown), however for variant 
E4 the results show that, although the MGP expression values between normal and tumor 
samples from each patient come across the threshold of significance (p=0.056), there is a 
strong tendency that indicates an increased expression of MGP in this type of tumors (Figure 
3.1 A and B), therefore, this non-significance could be attributed to high variability between 
patient’s samples. 
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Figure 3.1 Relative MGP gene expression in samples from patients with colon adenocarcinoma. (A) Relative 
MGP gene expression between samples from individual patients and MGP mRNA expression in HT29. (B) 
Relative MGP gene expression between control normal mucosa= 0.64±0.27 and tumoral mucosa= 4.39±1.86. 
Results were determined by paired t-test with difference between groups= -3.75, 95% CI [-7.61;0.11] P=0.056. 
Values are the mean of twenty independent replicates ± SEM. P value significant when P ≤ 0.05. Samples were all 
normalized concerning MCF-7 MGP expression. 
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These differences between samples may be explained by the genetic variability 
between patients, since mutations on MGP gene [15] or mutations in other genes or 
transcription factors that either interact with MGP or regulate it.  
In general, cancer is a disease with a complicated prognosis and development process. 
Although many studies have been previously conducted to try to understand how tumor cells 
proliferate and migrate to other organs [11] [38], only few studies could actually prove to 
influence this behavior in glioblastomas [16]. In that sense, the colon adenocarcinoma is an 
exceptional example on the investigation of cancer, since it has relatively slow development 
that allows researchers to explore specific genes involved in critical steps of its progression. 
KRAS, β-catenin, APC and C-MYC [2] are fine examples of particular oncogenes involved in 
colon adenocarcinoma progression, and are currently used as biomarkers for cancer prognosis 
and therapeutic decision [40]. Regarding MGP, these known oncogenes are not likely to 
directly influence its expression or specifically interact with MGP, still they can indirectly 
influence its expression, these way it would be interesting to understand whether it could be 
any correlation between MGP expression and presence of these oncogenes. During collection 
of clinical data we could only have access to presence of KRAS mutations, and indeed some 
patients were found to carry mutations in this oncogene.  
Nevertheless, our results contradict a previous study [15] where MGP was shown to be 
down-regulated in tumoral tissues. This study is the only one until now analyzing MGP in 
colon adenocarcinoma samples. Their authors used the same approach (as described in section 
Figure 3.2 MGP relative variation between Tumoral (MT) vs Normal Mucosa (MN). Values were 
calculated from the difference between tumoral and normal mucosa relative MGP gene expression.  
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methods and materials) to analyze paired samples from 80 patients with sporadic 
adenocarcinoma. According to their data, approximately 15% of the tumors presented a 
negative fold-change of more than 10. This discrepancy to our data could be associated to 
different populations, since previous study analyzed an Asiatic population (from Taiwan) 
while our analysis focused on a European Caucasian population (Portugal, Algarve). It also 
indicates that this analysis should be extended to 1) larger and 2) different populations. 
Nevertheless, in order to understand why a deregulation of MGP gene expression occurred in 
our samples we decided to further explore possible regulators of MGP. Indeed, MGP was 
previously shown to be increased in several tumor types, e.g. breast cancer [11] and gliomas 
[16]. Such analysis could help to understand the molecular mechanisms underlying MGP 
deregulation in cancer, and eventually find new biomarkers that would allow to detect the 
disease at an early stage. 
To assess if HT29 derived colon adenocarcinoma cell line was suitable for further 
analysis in vitro regarding MGP expression, we analyze trough qRT-PCR if this cells also 
present the same outline expression regarding MGP as we have seen in patient samples. In 
general, this cell line presents a very similar expression profile regarding MGP a high 
expression of this gene in HT-29 cells suggests that MGP expression in human colon 
adenocarcinoma samples most likely arise from tumor cells and not from its stroma. 
However, in the future it would be interesting to test this hypothesis through experiments 
involving in situ hybridization to detect MGP in biopsies. It also indicates that HT-29 cell line 
could be a good in vitro model to investigate MGP effects on cell proliferation, cell migration 
and cell invasion after RNA interference of MGP (ongoing experiments). The specific knock-
down of transcriptional regulators of MGP and its effects on MGP expression could also be 
tested in these cells. In sum, this analysis opens a new perspective on how these genes, i.e. 
MGP and its associated TF, may be interacting in the tumor microenvironment of colon 
adenocarcinomas. 
Therefore, our next experiments focused on determining the expression of 
transcription factors (RUNX2, FGF2, and RARα) that are known to regulate the transcription 
of MGP (23), and also the transcription factor CCBE1, in our group of 20 patients with colon 
adenocarcinoma. 
 
3.2 RUNX2 gene expression in patients with colon adenocarcinoma 
Previous experiments have shown that Runx2 was associated to tumor progression in 
colon adenocarcinoma by affecting the normal regulation of metastatic genes in murines [41]. 
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Furthermore, RUNX2 was shown to be associated with higher risk of colon cancer [42] and 
has been proposed as a possible prognostic factor [43]. Therefore, since RUNX2 is a known 
regulator of MGP transcription in Xenopus laevis and Zebrafish [10] [44], that also regulates 
MGP expression through parathyroid hormone in murines via PKA and ERK/MAPK 
signaling pathway  and was reported to be as well a regulator in breast cancer metastasis [45], 
we hypothesized whether this transcription factor could also be up-regulated in our samples. 
In fact, results showed a statistically significant up-regulation of RUNX2 expression level 
(P≤0.05) in tumor tissues compared with normal mucosa tissue (Figure 3.3 A and B). 
 
 
Figure 3.3 Relative expression of RUNX2 transcription factor in samples from patients with colon 
adenocarcinoma. (A) RUNX2 mRNA expression between samples from individual patients and RUNX2 
mRNA expression in HT29. (B) RUNX2 relative expression between control normal mucosa= 0.74±0.22 
and tumoral mucosa= 7.81±3.10. Results were determined by paired t-test with difference between groups= 
-7.07, 95% CI [-13.66;-0.47] P=0.0373. Values are the mean of sixteen independent replicates ± SEM. P 
value significant when P≤ 0.05. Samples were all normalized concerning MCF-7. 
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Figure 3.4 RUNX2 Relative variation between Tumoral vs Normal Mucosa. Values were calculated from the 
difference between tumoral and normal mucosa relative gene expression. 
 
 
Although the role of RUNX2 as regulator of MGP has been suggested from studies in 
Xenopus laevis [10], his possible effect on expression of MGP in colon adenocarcinoma has 
not been described yet. In fact, our study using a Pearson correlation analysis between the 
expression of RUNX2 and MGP, found no relationship between them (r=0.199; p= 0.46). This 
can be explained by signaling pathways involved in the regulation of RUNX2, and can 
indirectly regulate expression of MGP, and therefore, in this particular case it is not possible 
to affirm that up-regulation of RUNX2 is related to the tendency for higher levels of MGP. 
Indeed, given the known function of RUNX2 in cancer, such relation would be important to 
establish a mechanism for MGP deregulation in these tumors. Since the same pattern of 
expression for RUNX2 in human cell line HT29 (derived from adenocarcinomas) was shown 
to be the same as the one displayed in patients (figure 3.3 A), this brings a new insight to 
future experiments to test whether the effect of RUNX2 disturbs or not MGP regulation. 
 
 
3.2.1 Collagen and calcium-binding EGF domain-containing protein 1 (CCBE1) gene 
expression in patients with colon adenocarcinoma 
Collagen and calcium-binding EGF domain-containing protein 1 (CCBE1) has been 
associated with cell migration in ovarian cancer, where it was documented to be down-
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regulated during tumor progression [46]. CCBE1 was also shown to play a role in lymphatic 
vascular development in Hennekam syndrome, a disease characterized by intestinal and renal 
lymphatic dilation, dysmorphic facial appearance and mental retardation [47] [48] [49] The 
putative role of CCBE1 in other cancer types, including colon adenocarcinoma, was not 
established yet. The expression of CCBE1 levels in our samples from colon adenocarcinoma 
revealed an up-regulation of this gene that was statistically significant (P≤0.05), as shown in 
Figure 3.4 A and B. 
 
 
Figure 3.5 Relative expression of CCBE1 transcription factor in samples from patients with colon 
adenocarcinoma. (A) CCBE1 mRNA expression between samples from individual patients and CCBE1 mRNA 
expression in HT29. (B) CCBE1 relative expression between control normal mucosa= 0.03±0.02 and tumoral 
mucosa= 0.24±0.07. Results were determined by paired t-test with difference between groups= -0.20, 95% CI [-
0.35;-0.05] P=0.012. Values are the mean of sixteen independent replicates ± SEM. P value significant when P≤ 
0.05. Samples were normalizes concerning MCF-7. 
 
 Although this result may suggest a mechanism for MGP up-regulation in these 
samples, the putative association of CCBE1 to cancer is definitely far from being established. 
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In fact, CCBE1 association to cell migration in ovarian cancer was demonstrated to involve a 
down-regulation of this transcription factor expression due to a hypermethylation in the 
promoter that promotes cell migration, while the exact opposite effect was observed in our 
samples. Another concern is related to a general low expression of CCBE1 in all samples 
(Figure 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From the total number of patients analyzed, only 10 expressed this gene in tumor 
tissue, and 4 expressed this gene in normal tissue. It should also be noted that in patient #17 
we can observe an up-regulation of CCBE1 expression levels in normal tissue compared to 
tumor tissue, but still this difference is not statistical significant, however the Pearson 
correlation between CCBE1 and MGP expression in these samples was also high (r= 0.044; 
P=0.51), indicating an association between -regulation in MGP and CCBE1. As far as we 
know this was the first time that has been reported a relation between MGP and CCBE1 
expression in colon adenocarcinoma, and the biological mechanism underlying this possible 
regulation of MGP by CCBE1 is unknown. It would be important to have other clinical 
information regarding these patients, e.g. if they had other types of malignancies that may 
have some relation to the expression of CCBE1. In the future, it would be interesting to test 
CCBE1 effect on MGP in human colon adenocarcinoma cell lines. In fact, a previous analysis 
through qRT-PCR in HT29 cell line for CCBE1 demonstrated an inexistent expression of this 
gene, yet more analysis, such as blocking MGP expression and thought qRT-PCR analyse 
Figure 3.6 CCBE1 relative variation between Tumoral vs Normal Mucosa. Values were calculated from 
the difference between tumoral and normal mucosa relative gene expression. 
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CCBE1 gene expression, are required to confirm these previous data and if the relation 
between both genes can be consider as a biomarker for this type of cancer. 
 
 
3.2.2 Fibroblast Growth Factor 2 (FGF2) gene expression in patients with colon 
adenocarcinoma 
From all the transcription factors that are known to regulate MGP, FGF2 is the most 
studied in colon adenocarcinoma and colon tumor cell lines [50] [51] [52] [53], where it was 
shown to: i) contribute for the invasive potential (in HCT116A, HCT116B, LS180, LS174T 
and ARK1A cell lines) [52]; and ii) to promote proliferation and survival of colorectal cancer 
cells (NCI-H716) [53]. These in vitro studies, pose the hypothesis that FGF2 associated 
signaling pathways could be promoting the regulation of others genes that may lead to tumor 
progression, which ultimately could result in poor prognosis in colon adenocarcinoma. Here, 
attained data revealed a tendency for increased expression of this transcription factor in tumor 
tissue compared to normal tissue, but not in a significant manner (P= 0.085) (Figure 3.7 A and 
B). 
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Figure 3.7 Relative expression of FGF2 in samples from patients with colon adenocarcinoma. (A) FGF2 
gene expression between samples from individual patients and FGF2 mRNA expression in HT29. (B) FGF2 
relative expression between control normal mucosa= 0.38±0.19 and tumoral mucosa= 3.04±1.61. Results were 
determined by paired t-test with difference between groups= -2.66, 95% CI [-5.73;0.41] P=0.085. Values are the 
mean of sixteen independent replicates ± SEM. P value significant when P≤ 0.05. Samples were normalizes 
concerning MCF-7. 
 
The analysis of Pearson correlation between the relative variation expression of FGF2 
(Figure 3.8) and MGP relative variation shown a significant correlation between them 
(r=0.89; p≤0.0001). Although the association of FGF2 in colon adenocarcinoma can be 
supported by previous studies [54], a link between FGF2 and MGP expression in colon 
adenocarcinoma is still missing, and therefore it would be important to analyze this in the 
future. 
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In colon adenocarcinomas, FGF2 protein is known to be associated to the activation of 
multiple signaling cascades responsible for differentiation, growth and survival of cell, 
namely, PI3K/AKT, RAS/MAPK and PI3K/aPKC [54]. One consequence of this deregulation 
is the constant activation of KRAS signaling pathway, which will promote tumor cell 
differentiation. 
Experiments concerning treating colon adenocarcinoma HT-29 cells with FGF2 and 
analyzing its effects on MGP expression would shed some light on this hypothesis, still in 
ours previous analysis of FGF2 expression in tumor cell line HT-29 we observed an 
inexistent expression of FGF2 (Figure 3.7 A). 
 
 
3.2.3 Retinoic Acid Receptor α (RARα) gene expression in patients with colon 
adenocarcinoma 
Information regarding RARα involvement in cancer is scarce, although it has been 
recently associated to hematopoietic diseases, including leukemia [55]. Nevertheless, RARα 
is a known regulator of MGP (and therefore analyzing its expression in colon adenocarcinoma 
samples was relevant). However, our data indicated that despite being expressed in the colon 
it was not differentially expressed comparing tumor and normal samples (Figure 3.9 A and 
B). 
Figure 3.8 FGF2 relative variation between Tumoral (MT) vs Normal Mucosa (MN). Values were 
calculated from the difference between tumoral and normal mucosa relative gene expression. 
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Figure 3.9 Relative expression of RARα in samples from patients with colon adenocarcinoma. (A) RARα 
mRNA expression between samples from individual patients and RARα mRNA expression in TH29. (B) RARα 
relative expression between control normal mucosa= 34.44±13.29 and tumoral mucosa= 30.25±9.07. Results 
were determined by paired t-test with difference between groups= 4.19, 95% CI [-11.58;19,96] P=0,58. Values 
are the mean of sixteen independent replicates ± SEM. P value significant when P≤ 0.05. Samples were 
normalizes concerning MCF-7. 
 
RARα also showed the same positive Pearson correlation analysis (r= 0.84; P≤0.0001) 
as former established to FGF2. Therefore, it was not possible to relate RARα expression with 
MGP, indicating that this transcription factor is not likely to regulate MGP expression in 
human colon adenocarcinomas, still, presents a biological significance linked to MGP 
expression. 
Proliferative studies in RAR receptors with retinoids (metabolites of vitamin A, which 
are assumed that can interact with the two types of receptors RAR and RXR) in colon 
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adenocarcinoma cell lines MC-26 and LoVo have demonstrated that both cell line expresses 
RAR subtypes (RARα, RARβ, RARγ) and RXR receptors, however only MC-26 cell line 
appears to have an increase in growth provoked by retinoids, while the LoVo cell line 
remained unchanged with regard to proliferation. These results shows that the incapability of 
LoVo cells in response to retinoids do not appear to be related with the absence of RAR 
receptors, since they are present in these cells and hold the ability to synthesize the same 
retinoic acid receptor subtypes present in the MC-26. Other possible explanation for different 
proliferation results between cell lines is a presumed existence of other isoforms of RAR 
subtypes presents at MC-26, that possible do not exists in LoVo cell line [56]. The presence 
of different isoforms of RARα in colon adenocarcinomas may explain why such high 
variation between samples (Figure 3.10) and HT29 derived colon adenocarcinoma cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Figure 3.10 RARα relative variation between Tumoral (MT) vs Normal Mucosa (MN). Values were 
calculated from the difference between tumoral and normal mucosa relative gene expression. 
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4. Final remarks and Future Perspectives 
4.1 Final Remarks 
On the course of this work, several hypotheses were raised regarding the function of 
MGP and putative regulators in colon adenocarcinomas. To the best of our knowledge, 
nothing is known about which signaling pathways and transcription mechanisms affect MGP 
expression in cancer, and more specifically in colon adenocarcinoma. 
For this reason, we aimed to: i) investigate MGP dysregulation in colon adenocarcinomas; ii) 
Identify specific tumor stages where MGP gene becomes dysregulated; and iii) identify gene 
regulatory mechanisms associated with MGP deregulation in colon adenocarcinomas. Thus, 
according to our results: 
 
 There is a tendency for higher MGP expression in tumoral mucosa comparing to 
normal mucosa of colon adenocarcinomas, contradicting previous results showing an 
opposite regulation. 
 
 Consistent with this was the significant up-regulation of transcription factors Runx2 
and CCBE1 in tumoral mucosa;. 
 
 However, CCBE1 was the only transcription factor presenting an expression pattern 
that was strongly  correlated with MGP expression; 
 
 FGF2 data revealed a tendency for increased expression in tumoral tissue comparing 
to normal tissue, but not in a significant manner.  
 
 Although RARα was never shown to directly regulate MGP expression, this 
transcription factor along with FGF2 presented positive but still poor correlationa. 
 
 Interestingly, a preliminary analysis in a well-known cell line derived from colon 
adenocarcinoma, HT-29, presented similar expression levels of MGP and associated 
transcription factors to what was observed in patients. 
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In summary, it was not possible to establish a relation between up-regulation of MGP in 
colon adenocarcinomas with the age, gender or tumor staging. Also, until now it was not 
possible to determine if MGP is indeed a good biomarker in colon adenocarcinoma. In that 
sense, further experiments are required to uncover i) MGP association to tunoral mucosa, ii) 
MGP association to specific phases of colon adenocarcinoma tumor progression, and iii) 
cellular mechanisms underlying its regulation. For that, it will be crucial to raise the number 
of samples in order to attain statistical significance on the results obtained so far. Likewise, 
MGP higher expression in tumoral mucosa should be confirmed at the transcript level through 
in situ hybridization experiments, and at the protein level through immunohistochemistry 
experiments against MGP. Finally, preliminary data obtained from HT-29 revealed that this 
cell line may be a good in vitro model to investigate MGP tumorigenic mechanisms by testing 
effects on cell proliferation, cell migration and cell invasion after RNA interference of MGP 
(ongoing experiments). It will also be interesting to use these cells to study MGP regulatory 
mechanisms. 
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Appendix 1 Buffers and Solutions composition 
 
Solution- D: 
50ml Gu-Thio solution + 360 µl β-
mercaptoethanol. Store at 4ºC 
 
Gu-Thio solution: 250g of guanidine  
isothiocyanate/17.6ml of 0.75 M sodium 
citrate pH7.0/26.4ml of 10% N-lauroyl 
sarcosine (Na-salt)/293ml of DEPC water. 
Dissolve at 65ºC with stirring, filter 
sterilize (0.2µm), aliquot in 50-ml tubes 
and store at 4ºC. 
CIAA: chloroform and isoamyl alcohol 
49:1 (v/v) 
DEPC- treated water: 1ml of DEPC to 
1000ml of water: incubate O/N at 37ºC and 
autoclave 
 
PBS: 
16g NaCl (137mM), 0.4g KCl (2.7mM), 
5.8g Na2HPO4.12H2O (8.1mM), 0.4g 
KH2PO4 (1.47mM), water to a final 
volume 2L, adjust pH 7.0. 
 
Running Buffer: 
8.528g MES (50mM), 4.856g Tris 
(50mM), 0.8g SDS (0.1%), 0.23g (EDTA 
1mM), water to fill up final volume. 
 
Transfer Buffer (20x): 
10.2g Glycine (500mM), 13.08g Bistris 
(500mM), 0.7494g EDTA (20.5mM), 
water to fill up the final volume. 
Transfer Buffer (1x): 50ml Transfer Buffer 
(20x), 100ml METOH, 850ml water, 5µl 
4-Chloro-1-butanol.  
 
Blocking Solution: 
1.5g nonfat dry milk (Bio-Rad), PBST (1X 
PBS plus 0.2% Twee 20). 
 
Salts Solution (2x): 
7.1628g Na2HPO4.12H2O (10mM), 
116.880g NaCl (1M), 10ml Tween-20 
(1%), water to fill up to a final volume of 
1L. Dilution 1:2 for final solution.
                                             Sample Buffer (4x) 
 
                                                          Tris-HCL 320 mM at pH 6.8, 
                                                                                 2-mercaptoethanol 0.4M, 
                                                                                 8% SDS (m/v), 
                                                                                 0.024% (m/v) m-cresol purple,                                 
                                                                                 15% glycerol (v/v) 
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Appendix 1.1 
 
Table 1  List of primers 
hGADPH Forward 
hGADPH Reverse 
5’-TCAACGGATTTGGTCGTATTGGGCG-3’ 
5’-CTCGCTCCTGGAAGATGGTGATGGG-3’ 
hMGP E4 Forward 1 
hMGP E4 Reverse 5 
5’-TGCTGCTACACAAGACCCTGAGACTGA-3’ 
5’-GTAGCGTTCGCAAAGTCTGTAGTCATCAC-3’ 
hMGP E5 Forward 1 
hMGP E5 Reverse 4 
5’- TGCTGCTACACAAGACCCTGAGACTGA-3’ 
5’- CCGAAGTTTTCTTCTTTCTGCCACTCTCC-3’ 
hRunx2 Forward 
hRunx2 Reverse 
5’-GGAGTGGACGAGGCAAGAGTTTCACC-3’ 
5’-GCGGGACACCTACTCTCATACTGGG-3’ 
hFGF-2 Forward 
hFGF-2 Reverse 
5’-CAAAAACGGGGGCTTCTTCCTG-3’ 
5’-CCATCTTCCTTCATAGCCAGGTAACG-3’ 
hRARα Forward 
hRARα Reverse 
5’-TGTCCAAGGAGTCTGTGAGAAACGAC-3’ 
5’-GACACGTTGTTCTGAGCTGTTGTTCGTAG-3’ 
hCcbe1 Forward 
hCcbe1 Reverse 
5’-GAGATGGTTCTAAGGGGAGA-3’ 
5’-ATGTCAGCCAGCATAAGTAGCA-3’ 
 
 
 
 
